Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
114.60    3.80 (3.43%)
Bid:
114.80
Ask:
115.60
Spread: 0.80 (0.697%)
Market Cap: £187.88m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Disposal

11 Feb 2008 07:01

Yule Catto & Co PLC11 February 2008 Yule Catto & Co. plc Sale of James Robinson Yule Catto is an international producer of speciality chemicals, supplied toglobal customers for use in a wide range of industries includingpharmaceuticals, FMCG, paints and adhesives Yule Catto & Co plc ("Yule Catto" or the "Company") is pleased to announce thatit has exchanged conditional contracts with Vivimed Labs Limited ("Vivimed") forthe sale of the entire issued share capital of James Robinson Limited and otherassociated assets (together "James Robinson") for a consideration of $21.15million plus working capital of approximately $4.5 million. The considerationwill be paid as to $17.15 million plus the working capital amount in cash atcompletion and a further $4 million into escrow pending successful completion ofcertain product transfer arrangements. The completion of the sale is conditional on, amongst other things, Vivimedobtaining shareholder approval for the acquisition which is expected to beobtained by mid April 2008. The proceeds of the sale received by Yule Catto will be used to reduce theCompany's borrowings, and the transaction will be earnings accretive James Robinson carries on the development, manufacture and supply ofphotographic and photochromic chemicals and hair and other dyes. In the twelvemonths to 31 December 2006 it had sales of £17.8 million, an operating profit of£0.82 million and gross assets of £3.0 million. The James Robinson management team led by Dr Richard Smith will continue to runthe business. In addition, Yule Catto anticipates disposing of its interest in James RobinsonIndia (Private) Limited to its joint venture partner following the completion ofthe sale of James Robinson for a consideration of some $1.5 million. Adrian Whitfield, Chief Executive commented: "This sale is in line with YuleCatto's corporate strategy of delivering improved shareholder value from itsImpact Chemicals activities". 11 February 2008 ENQUIRIES: YULE CATTO Tel: 01279 442791Adrian Whitfield, Chief ExecutiveDavid Blackwood, Finance Director COLLEGE HILL Tel: 020 7457 2020Gareth DavidAnthony Parker This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Jan 20257:00 amRNSWinter trading statement
2nd Jan 20259:00 amRNSDirectorate Change
31st Oct 20247:00 amRNSTrading statement - Autumn 2024
17th Oct 20244:01 pmRNSHolding(s) in Company
14th Oct 20241:51 pmRNSHolding(s) in Company
27th Sep 202412:46 pmRNSHolding(s) in Company
19th Sep 20241:01 pmRNSHolding(s) in Company
13th Aug 20247:00 amRNSInterim results
18th Jul 202412:53 pmRNSChair succession and other board changes
17th May 20248:20 amRNSPost Stabilisation Notice
9th May 20242:29 pmRNSResults of AGM
9th May 20247:00 amRNSTrading Statement - Spring 2024
1st May 20247:00 amRNSDivestment of Compounds completed
25th Apr 20244:30 pmRNSDirector/PDMR Shareholding
25th Apr 20244:20 pmRNSDirector/PDMR Shareholding
17th Apr 202410:43 amRNSTender offer results
15th Apr 20247:00 amRNSDivestment of Compounds
12th Apr 20247:00 amRNSPricing of senior notes
9th Apr 20243:47 pmRNSPre Stabilisation Notice
9th Apr 20248:09 amRNSNotice of tender offer
9th Apr 20248:09 amRNSProposed offering of senior notes
28th Mar 20242:38 pmRNSDirector/PDMR Shareholding
28th Mar 20242:38 pmRNSDirector/PDMR Shareholding
28th Mar 20242:10 pmRNSAnnual Financial Report and Notice of AGM
12th Mar 20247:00 amRNSFinal Results
30th Jan 20247:00 amRNSTrading Statement
17th Jan 20242:58 pmRNSExternal Appointment
15th Nov 20237:00 amRNSTrading statement - Autumn 2023
3rd Nov 20232:54 pmRNSDirector/PDMR Shareholding
23rd Oct 20231:58 pmRNSDirector/PDMR Shareholding
18th Oct 20237:00 amRNSDirector/PDMR Shareholding
17th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20233:13 pmRNSHolding(s) in Company - CORRECTION
16th Oct 202312:06 pmRNSHolding(s) in Company
16th Oct 202312:03 pmRNSHolding(s) in Company
16th Oct 202311:57 amRNSHolding(s) in Company
16th Oct 20237:00 amRNSTotal Voting Rights
16th Oct 20237:00 amRNSPDMR and PCA Notification
13th Oct 20234:18 pmRNSHolding(s) in Company
13th Oct 202310:48 amRNSHolding(s) in Company
13th Oct 20237:00 amRNSResult of rump placing
12th Oct 20234:36 pmRNSResult of Equity Issue
12th Oct 202310:09 amRNSHolding(s) in Company
11th Oct 20239:39 amRNSHolding(s) in Company
11th Oct 20237:00 amRNSPDMR PCA Notification
10th Oct 20233:04 pmRNSHolding(s) in Company
10th Oct 202310:26 amRNSHolding(s) in Company
10th Oct 202310:26 amRNSHolding(s) in Company
9th Oct 20233:08 pmRNSHolding(s) in Company
9th Oct 20239:44 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.